IV Oxytocin Infusion Investigated to Reduce Post-Hysterectomy Opioid Consumption in Double-Blinded RCT
Background
Post-operative pain management remains a significant challenge, often relying heavily on opioids, which carry risks of side effects, dependence, and addiction. Finding effective non-opioid alternatives is crucial for improving patient outcomes and reducing the opioid burden. Oxytocin, a neuropeptide known for its roles in social bonding and uterine contraction, also exhibits analgesic properties through central mechanisms, making it a promising candidate for non-opioid pain relief. This trial explores its potential in the context of post-surgical pain.
Study Design
This double-blinded, placebo-controlled clinical trial is investigating the effect of IV oxytocin infusion on peri-operative opioid consumption. The study population consists of women scheduled for an elective, minimally invasive hysterectomy under general anesthesia at Beth Israel Deaconess Medical Center. Participants will be randomized to receive either IV oxytocin infusion or an IV placebo (normal saline). The primary endpoint is the reduction in opioid consumption following the hysterectomy procedure.
Why It Matters
If this trial demonstrates that IV oxytocin significantly reduces post-operative opioid consumption, it could revolutionize pain management protocols after gynecological surgeries. A successful outcome would provide a much-needed non-opioid alternative, potentially mitigating the risks associated with opioid use, such as addiction and adverse side effects. This could lead to improved patient recovery, shorter hospital stays, and a better overall surgical experience, offering clinicians a novel tool for enhanced pain control.
oxytocin
post-operative-pain
opioid-reduction
hysterectomy
clinical-trial
pain-management